IMT504 / Curative Biotech - LARVOL DELTA

IMT504 accelerates post-hepatectomy liver regeneration in mice with involvement of GLAST + Wnt1 + bone marrow stromal progenitors. (PubMed, Sci Rep) - "In summary, our findings identify IMT504 as a promising therapeutic candidate with strong pro-regenerative potential. Additionally, our data suggest that GLAST+ Wnt1+ BMSPs represent a unique bone marrow-derived population capable of giving rise to liver cells, further supporting their pro-regenerative role in liver regeneration."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

The antifibrotic potential of IMT504: modulation of GLAST + Wnt1 + bone marrow stromal progenitors and hepatic microenvironment. (PubMed, Stem Cell Res Ther) - "In summary, our findings identify IMT504 as a promising candidate molecule with potent antifibrotic properties, operating through both direct and indirect mechanisms, including the activation of GLAST + Wnt1 + BMSPs."

Journal • Stroma • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

Mesenchymal Cells Modulate Neuroma Enviroment in Rats and Humans and Prevents Postamputation Pain (IASP 2024) - "Our findings underscore the mechanistic relevance of MSCs and the translational therapeutic potential of IMT504 to engage non-neuronal cells for prevention of postamputation pain. The present study suggests that IMT504-dependent recruitment of endogenous MSCs within severely injured nerves and DRGs may prevent post-amputation pain by modifying the inflammatory scenario at relevant sites in the pain pathway. Reinforcing data in rat and human tissues supports the potential therapeutic value of IMT504 in patients suffering postamputation pain."

Preclinical • CNS Disorders • Musculoskeletal Pain • Orthopedics • Pain

ECDA000/02: Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Ministry of Public Health of the Province of La Rioja

Immunomodulating • New P1 trial